Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era

被引:8
作者
Hanzawa, Kyoko [1 ]
Momose, Shuji [2 ,3 ]
Higashi, Morihiro [2 ]
Tokuhira, Michihide [1 ]
Watanabe, Reiko [1 ]
Kajino, Kazunori [3 ]
Hino, Okio [3 ]
Itoyama, Shinji [2 ]
Kizaki, Masahiro [1 ]
Tamaru, Jun-Ichi [2 ]
机构
[1] Saitama Med Univ, Dept Hematol, Saitama Med Ctr, Saitama, Japan
[2] Saitama Med Univ, Dept Pathol, Saitama Med Ctr, Saitama, Japan
[3] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Tokyo 113, Japan
关键词
YB-1; diffuse large B-cell lymphoma; rituximab; P-glycoprotein; P-GLYCOPROTEIN EXPRESSION; HUMAN BREAST CANCERS; NUCLEAR EXPRESSION; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; R-CHOP; YB-1; CHEMOTHERAPY; DISEASE; LOCALIZATION;
D O I
10.3109/10428194.2010.522285
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The expression of YB-1 has been reported to predict poor clinical outcome in many human malignancies, including hematopoietic malignancies. In this study, we investigated the correlations between YB-1 expression and the clinicopathological features of patients with diffuse large B-cell lymphoma (DLBCL) in a single institution. The expression of YB-1 was analyzed in 168 cases by immunohistochemistry. Fifteen out of 168 cases (8.9%) showed cytoplasmic expression of YB-1. The expression of YB-1 was significantly associated with 5-year overall survival (OS) (p = 0.023). Rituximab plus CHOP therapy (n = 94) improved the 5-year survival rate in both YB-1-positive and -negative patients. In conclusion, the data presented in this report provide evidence that the cytoplasmic expression of YB-1 is a poor prognosis factor in DLBCL treated with CHOP therapy, whereas rituximab improves the survival of both YB-1-positive and -negative patients with DLBCL.
引用
收藏
页码:2054 / 2062
页数:9
相关论文
共 50 条
  • [41] Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
    Seo, Seyoung
    Hong, Jung Yong
    Yoon, Shinkyo
    Yoo, Changhoon
    Park, Ji Hyun
    Lee, Jung Bok
    Park, Chan-Sik
    Huh, Jooryung
    Lee, Yoonse
    Kim, Kyung Won
    Ryu, Jin-Sook
    Kim, Seok Jin
    Kim, Won Seog
    Yoon, Dok Hyun
    Suh, Cheolwon
    ONCOTARGET, 2016, 7 (47) : 76934 - 76943
  • [42] Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era
    Provencio, Mariano
    Martin, Paloma
    Garcia, Vanesa
    Candia, Antonio
    Sanchez, Antonio C.
    Bellas, Carmen
    LEUKEMIA & LYMPHOMA, 2010, 51 (11) : 2021 - 2030
  • [43] Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story
    Bari, A.
    Marcheselli, L.
    Sacchi, S.
    Marcheselli, R.
    Pozzi, S.
    Ferri, P.
    Balleari, E.
    Musto, P.
    Neri, S.
    Spiriti, M. A. Aloe
    Cox, M. C.
    ANNALS OF ONCOLOGY, 2010, 21 (07) : 1486 - 1491
  • [44] The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
    Kobayashi, T.
    Kuroda, J.
    Yokota, I.
    Tanba, K.
    Fujino, T.
    Kuwahara, S.
    Isa, R.
    Yamaguchi, J.
    Kawata, E.
    Akaogi, T.
    Uchiyama, H.
    Kaneko, H.
    Uoshima, N.
    Kobayashi, Y.
    Teramukai, S.
    Taniwaki, M.
    BLOOD CANCER JOURNAL, 2016, 6 : e383 - e383
  • [45] Use of rituximab in diffuse large B-cell lymphoma in the salvage setting
    Gisselbrecht, Christian
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (05) : 607 - 621
  • [46] Mechanism and Treatment of Rituximab Resistance in Diffuse Large B-cell Lymphoma
    Zou, Linqing
    Song, Guoqi
    Gu, Siyu
    Kong, Lingling
    Sun, Shiqi
    Yang, Li
    Cho, William C.
    CURRENT CANCER DRUG TARGETS, 2019, 19 (09) : 681 - 687
  • [47] Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
    Ennishi, D.
    Asai, H.
    Maeda, Y.
    Shinagawa, K.
    Ikeda, K.
    Yokoyama, M.
    Terui, Y.
    Takeuchi, K.
    Yoshino, T.
    Matsuo, K.
    Hatake, K.
    Tanimoto, M.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1217 - 1221
  • [48] Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
    Hu, Yunfei
    Ding, Ning
    Jin, Xuan
    Feng, Lixia
    Ping, Lingyan
    Song, Yuqin
    Zhu, Jun
    CANCER CELL INTERNATIONAL, 2014, 14
  • [49] Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era
    Sert, Fatma
    Kamer, Serra
    Saydam, Guray
    Anacak, Yavuz
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (06) : 1397 - 1402
  • [50] Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era
    Zaky, Amen Hamdy
    Bakry, Rania
    El-sayed, Mohamed I.
    Abd Elwanis, Mostafa
    Nabih, Ola
    HEMATOLOGY, 2014, 19 (07) : 412 - 416